The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Targeting RTK Signaling Pathways in Cancer
Open accessAbstract
The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of proliferation, differentiation and survival. The induction of these pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding. In cancer, constitutive and aberrant activations of components of those pathways result in increased proliferation, survival and metastasis. For instance, mutations affecting RTKs, Ras, B-Raf, PI3K and AKT are common in perpetuating the malignancy of several types of cancers and from different tissue origins. Therefore, these signaling pathways became prime targets for cancer therapy. This review aims to provide an overview about the most frequently encountered mutations, the pathogenesis that results from such mutations and the known therapeutic strategies developed to counteract their aberrant functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · cited 2×
“activated via ligand-induced dimerization that results in receptor auto-phosphorylation and tyrosine activation of RTKs’ substrates including phospholipase C-γ, mitogen-activated protein kinases and phosphatidylinositol 3-kinase [4–6] (Figure 1).”
BackgroundSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Mechanisms and functions of p38 MAPK signalling
Cuadrado, A., & Nebreda, A. R. (2010) · Biochemical Journal · doi:10.1042/bj20100323 · Cited by 1,676
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574 · cited 1×
“However, this effect appears to be more beneficial to patients carrying EGFR del19 mutations [20].”
BackgroundDvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2075 · Cited by 1,481
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
p38 MAP-Kinases pathway regulation, function and role in human diseases
Cuenda, A., & Rousseau, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.010 · Cited by 1,400
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Hemmings, B. A., & Restuccia, D. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011189 · Cited by 1,049
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · cited 1×
“Unlike Gefitinib and Erlotinib, Afatinib irreversibly (covalently) binds to proteins of ErbB family members and blocks their signaling pathways, thus promoting a sustained anti-proliferative activity [18,19].”
BackgroundCorless, C. L., Schroeder, A., Griffith, D., Town, A., McGreevey, L., Harrell, P., Shiraga, S., Bainbridge, T., Morich, J., & Heinrich, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.068 · Cited by 849
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Morrison, D. K. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011254 · Cited by 831
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 731
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 531
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 528
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M.-C., Hopper, T. M., Miller, C. G., Harrington, L. E., Onori, J. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0193 · Cited by 517
c-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 504
Role of p38 MAP Kinase Signal Transduction in Solid Tumors
Koul, H. K., Pal, M., & Koul, S. (2013) · Genes & Cancer · doi:10.1177/1947601913507951 · Cited by 484
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Renzo, M. F. D., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., & Giordano, S. (1995) · PubMed · Cited by 471
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 471
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
Targeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor
Kato, Y., Tapping, R. I., Huang, S., Watson, M. H., Ulevitch, R. J., & Lee, J.-D. (1998) · Nature · doi:10.1038/27234 · Cited by 436
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 427
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Furge, K. A., Zhang, Y.-W., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203859 · Cited by 410
Sakurai, T., Maeda, S., Chang, L., & Karin, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603499103 · Cited by 400
Distinct Roles for JNK1 and JNK2 in Regulating JNK Activity and c-Jun-Dependent Cell Proliferation
Sabapathy, K., Hochedlinger, K., Nam, S. Y., Bauer, A., Karin, M., & Wagner, E. F. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.028 · Cited by 396
Bhowmick, N. A., Zent, R., Ghiassi, M., McDonnell, M., & Moses, H. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106176200 · Cited by 388
(1992) · PubMed · Cited by 383
Goldstein, N. S., & Armin, M. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1331::aid-cncr1455>3.0.co;2-m · Cited by 364
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Juxtamembrane autoinhibition in receptor tyrosine kinases
Hubbard, S. R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1399 · Cited by 325
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
Xiao, S., Nalabolu, S. R., Aster, J. C., Ma, J., Abruzzo, L., Jaffe, E. S., Stone, R., Weissman, S. M., Hudson, T. J., & Fletcher, J. A. (1998) · Nature Genetics · doi:10.1038/ng0198-84 · Cited by 323
Radinsky, R., Risin, S. A., Fan, D., Dong, Z., Bielenberg, D. R., Bucana, C. D., & Fidler, I. J. (1995) · PubMed · Cited by 321
Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., & Wagner, E. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37156 · Cited by 307
Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Cancer Genome Project, Davies, H., Mohammadi, M., Futreal, P. A., Stratton, M. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 307
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
Hahn, K. A., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J.-P., Palmerini, F., et al. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.0190.x · Cited by 289
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Frost, M. J., Ferrao, P. T., Hughes, T. P., & Ashman, L. K. (2002) · PubMed · Cited by 281
Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
Meyer, K. B., Maia, A.-T., O'Reilly, M., Teschendorff, A. E., Chin, S.-F., Caldas, C., & Ponder, B. A. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060108 · Cited by 280
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
Ferracini, R., Renzo, M. F. D., Scotlandi, K., Baldini, N., Olivero, M., Lollini, P., Cremona, O., Campanacci, M., & Comoglio, P. M. (1995) · PubMed · Cited by 280
Jang, J., Shin, K., & Park, J.-G. (2001) · PubMed · Cited by 273
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1164 · Cited by 270
FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Kunii, K., Davis, L., Gorenstein, J., Hatch, H., Yashiro, M., Di Bacco, A., Elbi, C., & Lutterbach, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5229 · Cited by 269
Regulation of cellular functions by the ERK5 signalling pathway
Wang, X., & Tournier, C. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.11.003 · Cited by 264
Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies
Li, E., & Hristova, K. (2006) · Biochemistry · doi:10.1021/bi060609y · Cited by 258
Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., et al. (1999) · PubMed · Cited by 251
Mutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250
8p11 myeloproliferative syndrome: a review
Jackson, C. C., Medeiros, L. J., & Miranda, R. N. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.003 · Cited by 247
Kang, J. J., Dolled-Filhart, M. P., Ocal, I. T., Singh, B., Lin, C.-Y., Dickson, R. B., Rimm, D. L., & Camp, R. L. (2003) · PubMed · Cited by 237
Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
Gelsi-Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rougé, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0128 · Cited by 234
Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 222
Massion, P. P., Kuo, W.-L., Stokoe, D., Olshen, A. B., TRESELER, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., et al. (2002) · PubMed · Cited by 222
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
McKay, J. A., Murray, L. J., Curran, S., Ross, V. G., Clark, C., Murray, G. I., Cassidy, J., & McLeod, H. L. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00234-4 · Cited by 220
Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.
Chen, N., Nomura, M., She, Q., Ma, W. Y., Bode, A. M., Wang, L. Q., Flavell, R. A., & Dong, Z. (2001) · PubMed · Cited by 213
Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198
Adams, V. R., & Leggas, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.022 · Cited by 197
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2003-y · Cited by 195
Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., de Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5485 · Cited by 190
Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R., et al. (2001) · Blood · doi:10.1182/blood.v98.13.3778 · Cited by 189
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
Wardelmann, E., Thomas, N., Merkelbach-Bruse, S., Pauls, K., Speidel, N., Büttner, R., Bihl, H., Leutner, C. C., Heinicke, T., & Hohenberger, P. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70097-8 · Cited by 189
She, Q., Chen, N., Bode, A. M., Flavell, R. A., & Dong, Z. (2002) · PubMed · Cited by 186
Mechanisms of FGFR-mediated carcinogenesis
Ahmad, I., Iwata, T., & Leung, H. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.004 · Cited by 184
Mehta, P. B., Jenkins, B. L., McCarthy, L., Thilak, L., Robson, C. N., Neal, D. E., & Leung, H. Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206154 · Cited by 179
Gorringe, K. L., Jacobs, S., Thompson, E. R., Sridhar, A., Qiu, W., Choong, D. Y. H., & Campbell, I. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0502 · Cited by 171
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas
Puputti, M., Tynninen, O., Sihto, H., Blom, T., Mäenpää, H., Isola, J., Paetau, A., Joensuu, H., & Nupponen, N. N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0085 · Cited by 171
Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Mühling, J., Hofele, C., Radlwimmer, B., Lichter, P., & Joos, S. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.01.005 · Cited by 165
A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes
Garcia, M. J., Pole, J. C. M., Chin, S.-F., Teschendorff, A., Naderi, A., Ozdag, H., Vias, M., Kranjac, T., Subkhankulova, T., Paish, C., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208741 · Cited by 164
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
Kim, M. S., Jeong, E. G., Yoo, N. J., & Lee, S. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604212 · Cited by 163
Miller, C. T., Lin, L., Casper, A. M., Lim, J., Thomas, D. G., Orringer, M. B., Chang, A. C., Chambers, A. F., Giordano, T. J., Glover, T. W., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209057 · Cited by 161
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507200102 · Cited by 159
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Targeting EGFR in Colorectal Cancer
Messersmith, W. A., & Ahnen, D. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806778 · Cited by 156
Schiering, N., Knapp, S., Marconi, M., Flocco, M. M., Cui, J., Perego, R., Rusconi, L., & Cristiani, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734128100 · Cited by 156
van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155
Davies, C. C., & Tournier, C. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110641 · Cited by 153
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. P., & Etten, R. A. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00053-4 · Cited by 152
Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., & Stahl, U. (2002) · The Journal of Pathology · doi:10.1002/path.1207 · Cited by 152
Therapeutic targeting of c-KIT in cancer
Ashman, L. K., & Griffith, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740010 · Cited by 147
Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi‐Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-245 · Cited by 139
Sarker, D., Molife, R., Evans, T. R. J., Hardie, M., Marriott, C., Bützberger, P., Morrison, R., Fox, J. A., Heise, C. C., Louie, S. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1466 · Cited by 138
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer
Chang, Q., Zhang, Y., Beezhold, K., Bhatia, D., Zhao, H., Chen, J., Castranova, V., Shi, X., & Chen, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.037 · Cited by 137
Buchanan, S. G., Hendle, J., Lee, P. S., Smith, C. R., Bounaud, P., Jessen, K., Tang, C. M., Huser, N. H., Felce, J. D., Froning, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0477 · Cited by 135
Howes, A. L., Chiang, G. G., Lang, E. S., Ho, C., Powis, G., Vuori, K., & Abraham, R. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0698 · Cited by 135
Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Underiner, T. L., Herbertz, T., & Miknyoczki, S. J. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010007 · Cited by 133
Zhao, J., Roth, J., Bode‐Lesniewska, B., Pfaltz, M., Heitz, P. U., & Komminoth, P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10035 · Cited by 132
Smith, J. S., Wang, X.-Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.495 · Cited by 125
Montemurro, F., Donadio, M., Clavarezza, M., Redana, S., Jacomuzzi, M. E., Valabrega, G., Danese, S., Vietti-Ramus, G., Durando, A., Venturini, M., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-318 · Cited by 123
Wang, X., Merritt, A. J., Seyfried, J., Guo, C., Papadakis, E. S., Finegan, K. G., Kayahara, M., Dixon, J., Boot-Handford, R., Cartwright, E. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.336-345.2005 · Cited by 121
Toffalini, F., & Demoulin, J. (2010) · Blood · doi:10.1182/blood-2010-04-279752 · Cited by 121
Campbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0513 · Cited by 121
Regulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction
Kopera, H. C., & Guan, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212803200 · Cited by 110
Bernard‐Pierrot, I., Gruel, N., Stransky, N., Vincent‐Salomon, A., Reyal, F., Raynal, V., Vallot, C., Pierron, G., Radvanyi, F., & Delattre, O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1360 · Cited by 103
Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 102
Hayashi, M., Fearns, C., Eliceiri, B. P., Yang, Y. C., & Lee, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4540 · Cited by 101
Richardson, P. G. G., Eng, C., Kolesar, J., Hideshima, T., & Anderson, K. C. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.681376 · Cited by 101
Expression of the FGFR1 gene in human breast‐carcinoma cells
Jacquemier, J. D., Adélaı̈de, J., Parc, P., Penault-Llorca, F. M., Planche, J., deLapeyrière, O., & Birnbaum, D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590314 · Cited by 86
Hecht, M., Papoutsi, M., Tran, H., Wilting, J., & Schweigerer, L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1014 · Cited by 83
A genomic analysis of adult T-cell leukemia
Choi, Y. L., Tsukasaki, K., O’Neill, M. C., Yamada, Y., Onimaru, Y., Matsumoto, K., Ohashi, J., Yamashita, Y., Tsutsumi, S., Kaneda, R., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209898 · Cited by 83
Agarwal, E., Chaudhuri, A., Leiphrakpam, P. D., Haferbier, K. L., Brattain, M. G., & Chowdhury, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-145 · Cited by 79
Molecular and cellular pathogenesis of melanoma initiation and progression
Regad, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1324-2 · Cited by 77
Self-citationKumabe, T., SOHMA, Y., Kayama, T., Yoshimoto, T., & Yamamoto, T. (1992) · PubMed · Cited by 75
FGFR3 mutations in prostate cancer: association with low-grade tumors
Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma
Nord, H., Segersten, U., Sandgren, J., Wester, K., Busch, C., Menzel, U., Komorowski, J., Dumanski, J. P., Malmström, P., & de Ståhl, T. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24954 · Cited by 75
Previdi, S., Abbadessa, G., Dalò, F., France, D. S., & Broggini, M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0277 · Cited by 66
Bowles, D. W., Ma, W. W., Senzer, N. N., Brahmer, J. R., Adjei, A. A., Davies, M. A., Lazar, A. J., Vo, A. C. H., Peterson, S., Walker, L. N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
Sleijfer, S., Wiemer, E. A. C., Seynaeve, C., & Verweij, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-719 · Cited by 62
Regulation of anoikis by Cdc42 and Rac1
Cheng, T., Symons, M. H., & Jou, T. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.002 · Cited by 60
Ren, M., Li, X., & Cowell, J. K. (2009) · Blood · doi:10.1182/blood-2009-03-212704 · Cited by 57
Molecular Determinants of Tumor Recurrence in The Urinary Bladder
Liang Cheng, C., Zhang, S., Davidson, D. D., MacLennan, G. T., Koch, M. O., Montironi, R., & Antonio Lopez-beltran, B. (2009) · Future Oncology · doi:10.2217/fon.09.50 · Cited by 57
Arai, H., Ueno, T., Tangoku, A., Yoshino, S., Abe, T., Kawauchi, S., Oga, A., Furuya, T., Oka, M., & Sasaki, K. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00106-7 · Cited by 55
Munugalavadla, V., Mariathasan, S., Slaga, D., Du, C., Berry, L., Rosario, G. D., Yan, Y., Boe, M., Sun, L., Friedman, L. S., et al. (2013) · Oncogene · doi:10.1038/onc.2012.594 · Cited by 43
Blocking the mTOR pathway: a drug discovery perspective
García-Echeverría, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390451 · Cited by 27
Wang, X., Pesakhov, S., Harrison, J. S., Kafka, M., Danilenko, M., & Studzinski, G. P. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.10.003 · Cited by 25
Chou, A. Y., Dekker, N. P., & Jordan, R. C. (2009) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2008.12.050 · Cited by 23
Cited by
EGFR-TKIs resistance via EGFR-independent signaling pathways
Liu, Q., Yu, S., Zhao, W., Qin, S., Chu, Q., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0793-1 · Cited by 405
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y.-S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0801-5 · Cited by 395
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Self-citationDegradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
Metadata
- Authors
- Regad, T.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-09-03
- Volume
- 7
- Issue
- 3
- Pages
- 1758-1784
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W1773455335
- Cited by
- 380
- References
- 177
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.